Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Personalis Temettü

Temettü kriter kontrolleri 0/6

Personalis şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	0.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.44
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Sep 14

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Jul 25

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Apr 19

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Mar 02

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PSNL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PSNL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Personalis Piyasaya Karşı Temettü Getirisi

PSNL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PSNL)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Life Sciences)	0.3%
Analist tahmini (PSNL) (3 yıla kadar)	0%

Önemli Temettü: PSNL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PSNL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PSNL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PSNL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Personalis Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Personalis, Inc. announced that it expects to receive $17.745 million in funding from Tempus AI, Inc

Personalis, Inc. Revises Earnings Guidance for the Year 2024

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Personalis, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Consensus estimates of losses per share improve by 11%

Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Personalis, Inc. to Report Q1, 2024 Results on May 08, 2024

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Full year 2023 earnings: EPS misses analyst expectations

Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Personalis, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Personalis, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Personalis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

New minor risk - Shareholder dilution

Personalis, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Price target decreased by 13% to US$5.90

Personalis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Personalis, Inc. Announces Board Changes

High number of new directors

Personalis, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 23% to US$6.80

Full year 2022 earnings: EPS misses analyst expectations

Personalis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Price target decreased to US$8.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Personalis, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Personalis, Inc. Provides Earnings Guidance for the Year 2022

Personalis, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$16.20

Personalis, Inc.(NasdaqGM:PSNL) dropped from Russell 2000 Growth Index

The Prognosis For Personalis

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Price target decreased to US$21.83

High number of new directors

Co-Founder exercised options to buy US$266k worth of stock.

Personalis, Inc. to Report Q1, 2022 Results on May 04, 2022

Co-Founder notifies of intention to sell stock

Personalis Announces Issuance of Additional US Patent Related to the Next Personal Platform

Personalis, Inc., Annual General Meeting, May 17, 2022

Co-Founder notifies of intention to sell stock

High number of new directors

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to US$25.83

Personalis, Inc. Provides Earnings Guidance for the Full Year 2022

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Price target decreased to US$29.50

Forecast to breakeven in 2024

Personalis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Personalis: Getting Personal Again

Co-Founder notifies of intention to sell stock